Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other Cancers
Conditions
Interventions
Enoblituzumab Schedule 1
Pembrolizumab
+2 more
Locations
20
United States
Mayo Clinic - AZ
Scottsdale, Arizona, United States
Christiana Care Health Services, Inc.
Newark, Delaware, United States
Mayo Clinic - FL
Jacksonville, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
Norton Cancer Institute Research Program
Louisville, Kentucky, United States
University of Maryland Greenbaum Cancer Center
Baltimore, Maryland, United States
Start Date
July 1, 2015
Primary Completion Date
August 18, 2021
Completion Date
August 18, 2021
Last Updated
August 11, 2025
NCT04541381
NCT05671510
NCT07177937
NCT02621021
NCT03050268
NCT07209189
Lead Sponsor
MacroGenics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions